SG Americas Securities LLC Acquires 6,774 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

SG Americas Securities LLC increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 43.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,498 shares of the company’s stock after purchasing an additional 6,774 shares during the period. SG Americas Securities LLC’s holdings in Harmony Biosciences were worth $774,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HRMY. GAMMA Investing LLC boosted its stake in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares in the last quarter. Mendota Financial Group LLC boosted its stake in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after acquiring an additional 965 shares in the last quarter. CWM LLC boosted its stake in Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after acquiring an additional 775 shares in the last quarter. Quarry LP acquired a new stake in Harmony Biosciences in the second quarter valued at approximately $62,000. Finally, Quantbot Technologies LP acquired a new stake in Harmony Biosciences in the third quarter valued at approximately $74,000. 86.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey M. Dayno sold 19,293 shares of Harmony Biosciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock valued at $2,831,679 over the last 90 days. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Trading Up 1.0 %

Shares of Harmony Biosciences stock opened at $38.82 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The firm has a fifty day moving average price of $35.20 and a 200 day moving average price of $35.22. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The stock has a market cap of $2.21 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. During the same quarter last year, the company posted $0.63 earnings per share. The firm’s revenue was up 16.0% compared to the same quarter last year. Equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

HRMY has been the subject of several recent analyst reports. Oppenheimer restated an “outperform” rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. Mizuho raised their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, October 10th. Raymond James reiterated an “outperform” rating and set a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald lifted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Harmony Biosciences has an average rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.